Premium
Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice
Author(s) -
Wuestefeld Torsten,
Klein Christian,
Streetz Konrad L.,
Beraza Naiara,
Schölmerich Jürgen,
Burgart Lawrence J.,
Zender Lars,
Kubicka Stefan,
Gores Gregory J.,
Manns Michael P.,
Trautwein Christian
Publication year - 2005
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.20912
Subject(s) - cholestasis , glycoprotein 130 , sepsis , medicine , immunology , acute phase protein , liver injury , biology , endocrinology , inflammation , interleukin 6
Chronic cholestasis is associated with increased bacterial infections and sepsis resulting in higher mortality in humans. In the current study, we investigated the relevance of gp130‐dependent pathways after bile duct ligation (BDL). BDL was performed in conditional gp130 knockout (loxP/Cre system) mice and respective controls. Liver injury, regulation of the acute phase response, and the impact on survival and bacterial infections were determined. Acute BDL resulted in increased IL‐6 levels, Stat3 activation, and an increase in acute‐phase proteins (serum‐amyloid‐A [SAA]), which was blocked in gp130‐deleted animals. In addition, the antimicrobial gene hepcidin was regulated in a gp130‐dependent manner after BDL. During chronic cholestasis Stat3 activation was dramatically reduced, while high SAA levels were maintained via gp130‐dependent signaling. Inhibition of gp130‐dependent pathways resulted in higher mortality and liver damage, which was associated with higher infiltration of immune‐activated cells and increased germ number in the liver. In conclusion , during acute and chronic cholestasis, the gp130 system is essential for controlling the acute‐phase response. Lack of gp130 expression results in pronounced bacterial growth in bile and liver after BDL, which is associated with higher mortality. Activation of gp130‐dependent pathways after BDL is essential and appears to be a therapeutic target during cholestasis. (H EPATOLOGY 2005;42:1082–1090.)